Mobia Medical, Inc. (NASDAQ:MOBI – Get Free Report) insider Chase Leavitt acquired 2,000 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was acquired at an average price of $10.30 per share, for a total transaction of $20,600.00. Following the acquisition, the insider owned 5,000 shares in the company, valued at approximately $51,500. The trade was a 66.67% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Mobia Medical Stock Performance
Shares of NASDAQ MOBI opened at $10.71 on Thursday. The stock’s 50-day simple moving average is $11.42. The firm has a market cap of $356.54 million and a price-to-earnings ratio of -0.53. Mobia Medical, Inc. has a fifty-two week low of $9.85 and a fifty-two week high of $15.29. The company has a quick ratio of 12.80, a current ratio of 13.28 and a debt-to-equity ratio of 0.04.
Mobia Medical (NASDAQ:MOBI – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The company had revenue of $13.51 million during the quarter. The firm’s revenue for the quarter was up 102.4% compared to the same quarter last year. On average, sell-side analysts forecast that Mobia Medical, Inc. will post -2.63 earnings per share for the current fiscal year.
Institutional Trading of Mobia Medical
Wall Street Analyst Weigh In
A number of research firms recently commented on MOBI. Zacks Research raised shares of Mobia Medical to a “hold” rating in a research report on Wednesday, June 3rd. Bank of America began coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $16.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on Mobia Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. The Goldman Sachs Group began coverage on Mobia Medical in a research report on Tuesday, June 2nd. They set a “buy” rating and a $31.00 target price on the stock. Finally, Wolfe Research began coverage on Mobia Medical in a report on Tuesday, June 2nd. They issued an “outperform” rating for the company. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.75.
Check Out Our Latest Stock Report on MOBI
About Mobia Medical
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.
Featured Stories
- Five stocks we like better than Mobia Medical
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Mobia Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mobia Medical and related companies with MarketBeat.com's FREE daily email newsletter.
